Enterococcus faecalis and Enterococcus faecium infections are increasingly difficult to treat due to high levels of resistance to antibiotics. PlyV12, a bacteriophage lytic enzyme, was isolated and shown to effectively kill both E. faecalis and E. faecium (including vancomycin-resistant strains), as well as other human pathogens. We propose its development and use as an alternative therapeutic tool.
bers are characterized by contractile tails and icosahedral heads (2, 7) . PlyV12 is a proposed amidase that exhibits a substantial lytic effect on multiple E. faecalis strains. Significantly, PlyV12 also lyses vancomycin-resistant strains of E. faecalis and strains of the closely related enterococcal pathogen E. faecium. Distinct from other reported lysins, PlyV12 was also found to be active against several disease-causing streptococcal and staphylococcal strains, making it one of the first lysins to demonstrate a spectrum of activity outside that of the host and closely related bacterial strains. This broad activity spectrum suggests the presence of a unique cell wall carbohydrate epitope common to these diverse human pathogens.
PlyV12 was identified based on a previously described genetic screening process (12) whereby a ⌽1 genomic library was screened for lytic agents active against E. faecalis strain V12. A 945-bp open reading frame was identified after DNA sequencing of a lytic clone. The open reading frame translates into a protein of 314 amino acids with a molecular mass of approximately 34 kDa. The plyV12 gene was initially cloned into several Escherichia coli expression systems; however, the enzyme yields were very low in all cases. PlyV12 (as other lytic enzymes) is translated without a leader sequence; thus, it remains in the cytoplasm, where it cannot exert an effect on its peptidoglycan substrate, therefore making it possible to be expressed in a wide range of systems. Subsequently, the plyV12 gene and approximately 100 bp of the flanking sequence were amplified by PCR and cloned into the E. coli-Bacillus shuttle vector pDG148 (21) , yielding pPY1. plyV12 was then expressed in Bacillus megaterium strain WH320 (MoBiTec, Marco Island, Fla.) by induction with isopropyl-␤-D-thiogalactopyranoside for 1 h, at which time the culture was centrifuged. The pelleted bacteria were suspended in 100 ml of a lysis reagent, BugBuster (diluted from a 10ϫ concentration to a 1ϫ concentration in phosphate-buffered saline [PBS] containing 100 g of lysozyme/ml) (Novagen, San Diego, Calif.). This cell lysate was allowed to remain at 37°C for 1 h, followed by centrifugation at 4,000 rpm in an Eppendorf centrifuge to pellet the cell debris. The supernatant containing the crude lysin was diluted 1:3 in 50 mM morpholineethanesulfonic acid at pH 6.7 prior to being loaded on three 5-ml HiTrap SP HP columns (Amersham Biosciences, Piscataway, N.J.) connected in a series. The columns were washed with the 50 mM morpholineethanesulfonic on November 10, 2017 by guest http://jb.asm.org/ acid buffer until the optical density at a wavelength of 280 nm (OD 280 ) reached the baseline. PlyV12 was eluted with a 20-column-volume linear gradient to a concentration of 1 M sodium chloride (NaCl), and a peak at ϳ330 mM NaCl was found to contain the lytic activity. Furthermore, sodium dodecyl sulfate-polyacrylamide gel electrophoresis revealed a 34-kDa band corresponding to this peak, which matched the predicted size of PlyV12. Fractions constituting the peak were pooled and concentrated to 25 U/ml (see below) in an Amicon Ultra unit with a cutoff of 10 kDa (Millipore, Billerica, Mass.). The final PlyV12 sample was purified Ͼ85% based on spot densitometry (AlphaImager; Alpha Innotech, San Leandro, Calif.) of the gel images of crude and purified PlyV12 that were obtained by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. PlyV12 lytic activity was expressed in units per milliliter, in which units represent the reciprocal of the highest dilution of enzyme resulting in a 50% reduction in bacterial OD 600 in 15 min. Subsequent bacterial killing experiments were carried out with a PlyV12 preparation of 25 U/ml.
For the lysin killing assays, the bacterial strains to be assayed were grown to mid-logarithmic phase in brain heart infusion broth, pelleted, and resuspended in PBS at pH 7.4 to an OD 600 of 2.0. The pH profile experiments for PlyV12 activity were performed after the bacterial cells were resuspended in 100 mM acetate buffer at pH 5.2, 100 mM morpholinepropanesulfonic acid at pH 6.5, or 100 mM Tris at pH 7.5 or 8.5 instead. A 100-l volume of bacterial suspension was mixed with 100 l of PlyV12 at 25 U/ml. For the OD assays, the OD 600 of the mixture was monitored every 15 s with shaking over a 15-min period on an automated 96-well plate reader (SpectraMax Plus 384 ; Molecular Devices, Sunnyvale, Calif.). For viability assays, the mixture of a bacteria and PlyV12 was incubated at room temperature with gentle shaking for specified amounts of time, and at designated time points, aliquots were removed, serially diluted, and plated on agar plates for viability counts.
An alignment of the PlyV12 sequence from E. faecalis bacteriophage ⌽1 with lysins from bacteriophages of Streptococcus agalactiae (a group B streptococcus), S. pyogenes, S. pneumoniae, Streptococcus mitis, and Streptococcus thermophilus revealed similarities primarily limited to the amino termini of these molecules, which correspond to the catalytic domains of most lysins (Fig. 1) . Since several of these lysins are known to confer N-acetylmuramyl-L-alanine amidase activity, PlyV12 may also be an amidase. The diminished sequence similarity among the carboxy-terminal portions of all these lysins sug- FIG. 2 . pH profile of PlyV12 activity. PlyV12 activity against E. faecalis strain V12 was tested at pHs 5.2, 6.5, 7.5, and 8.5 . PlyV12 activity was measured by an OD assay and plotted as the percent decrease in OD 600 in 15 min. gests that they have distinct cell wall binding epitopes and hence different bacterial specificities. PlyV12 was found to have maximal activity at about pH 6.0 while retaining partial yet significant activity at pH values of 5.0 and 7.5 (Fig. 2) . The activity decreased rapidly at higher pHs, resulting in near inactivation at pH 8.5, a profile common among bacteriophage lysins (11) . Although not optimum, all subsequent assays were carried out in PBS at pH 7.4 to determine the PlyV12 activity under physiological conditions. While PlyV12 functioned well at physiological salt concentrations, sodium chloride at concentrations upwards of 250 mM deteriorates its activity (results not shown).
In addition to killing its host bacterial strain, E. faecalis strain V12, PlyV12 also had lytic activity against 14 clinical and laboratory E. faecalis and E. faecium strains tested, including two vancomycin-resistant E. faecalis strains and three vancomycin-resistant E. faecium strains (Table 1 and Fig. 3 ). Interestingly, PlyV12 also exhibited a significant killing effect on strains of pathogenic streptococci, including S. pyogenes (a group A streptococcus), which are responsible for pharyngitis, toxic shock syndrome, and rheumatic fever (4); group B streptococci, which are responsible for neonatal meningitis (1); and group C streptococci, which constitute an emerging pathogen group causing diseases similar to those caused by S. pyogenes (18) . While the sequence alignment of PlyV12 from the E. faecalis bacteriophage ⌽1 with lysins of group A and group B streptococcal bacteriophages (from S. pyogenes and S. agalactiae, respectively) ( Fig. 1) suggests that these lysins target different cell wall epitopes, the ability of PlyV12 to lyse strains of E. faecalis, S. pyogenes, and group B streptococci shows that PlyV12 recognizes a receptor common among these different pathogens. Additionally, PlyV12 had some lytic effect against Staphylococcus aureus, another high-level, antibiotic-resistant nosocomial pathogen that is responsible for sepsis, necrotizing pneumonia, and toxic shock syndrome (22) .
The assays described above were carried out using a measurement of OD, which corresponds with bacterial viability. However, to better quantitate the extent of bacterial killing, a direct viability assay was performed with E. faecalis strain V12 incubated with PlyV12. The results revealed a Ͼ4-log reduc- FIG. 3 . Range of activity of PlyV12. PlyV12 activity against enterococcal, streptococcal, and staphylococcal strains was measured as the rate of decrease in OD per minute, expressed in milliunits of OD 600 per minute. This initial velocity measurement allowed direct comparison of PlyV12 activities among bacterial species. VRE, vancomycin-resistant enterococci. (Inset) Viability assay of E. faecalis strain V12 treated with PlyV12. Viability was measured in CFU per milliliter. E. faecium strains EFSK-2, EFSK-16, and EFSK-33 as well as E. faecalis strains JH2-2, EF-24, EF-25, EF-1, and EF-17 were obtained from A. Tomasz. All other strains are part of the Rockefeller University Bacteria Collection. VOL. 186, 2004 NOTES 4811 on November 10, 2017 by guest http://jb.asm.org/ tion in viability when the mixture was exposed to 2.5 U of PlyV12 for 15 min, which corresponds to a drop of 200 mOD 600 /min in the OD assay (Fig. 3, inset) . The viability of this strain continued to decrease upon further incubation with PlyV12. PlyV12 has bactericidal activity against all strains of E. faecalis and E. faecium tested, which is very significant for clinical strains and strains resistant to the antibiotic vancomycin. Vancomycin is considered the last line of defense against many bacterial pathogens that are already resistant to other available antibiotics (3) . Enterococci are a leading cause of nosocomial infections, and treating these infections with conventional antibiotics has become increasingly difficult in light of the acquisition of antibiotic resistance genes by these organisms. It is anticipated that soon enterococci will be untreatable by current antibiotics, and alternative means of combating infections caused by these organisms will be urgently needed. We have shown that PlyV12 is a viable candidate for such an antienterococcal therapeutic agent.
PlyV12 exhibited significant lethal activity against other pathogens, such as S. pyogenes and group B, C, E, and G streptococci, with minimal effects against commensal bacteria (with the exception of Streptococcus gordonii). This finding suggests a broader application for this lysin whereby PlyV12 is used as a therapeutic agent specific for multiple pathogens that are responsible for serious infections. While the organization of its primary structure and the nature of its enzymatic activity make PlyV12 consistent with other bacteriophage lysins previously studied, PlyV12 is believed to be the first bacteriophage lysin described to have activity against Enterococcus species. In addition, previously studied bacteriophage lysins generally have a narrow spectrum of activity specific to the host bacterial species from which the phage was isolated. PlyV12's comparatively broad spectrum of activity against numerous bacterial strains indicates that this is a truly unique enzyme. Furthermore, the PlyV12 binding activity determined in this study suggests a previously undiscovered surface structure common to several different pathogens, which could serve as a target in the development of new antibiotics.
Nucleotide sequence accession number. The nucleotide sequence of PlyV12 has been deposited into GenBank under accession number AY581208.
